Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anoro

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

- PMLiVE

GSK to develop Ionis hepatitis B drugs

Competing with rivals Gilead to find cure for 200 million people

- PMLiVE

GSK preps filings for BCMA-targeting multiple myeloma drug

On course to file before end of year

- PMLiVE

GSK files anaemia drug daprodustat in Japan, its first market

Around 3.5 million people in Japan could access the drug

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

- PMLiVE

Hal Barron touts new drive to improve GSK’s research output

'Consensus-led' research being replaced with bold decision-making

- PMLiVE

ViiV builds case for switching to its two-drug HIV combinations

Taking aim at rival Biktarvy

- PMLiVE

McCann’s Breath of Life diagnostic wins Cannes Lion prize

Grand Prix awarded for first time in three years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links